Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

Vertex Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Alpha1-Antitrypsin Deficiency

Treatments: Drug: Placebo; Drug: VX-864

Study type: Interventional

Funder types: Industry

Identifiers

NCT04474197

VX19-864-101

2019-004881-16 (EudraCT Number)

Details and patient eligibility

About

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.

Enrollment: 44 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Subjects must have a PiZZ genotype confirmed at screening
• Plasma AAT levels indicating severe deficiency at screening

Key Exclusion Criteria:

• History of a medical condition that could negatively impact the ability to complete the study
• Solid organ, or hematological transplantation or is currently on a transplant list
• History of use of gene therapy or RNAi therapy at any time previously

Other protocol defined Inclusion/Exclusion criteria may apply

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

44 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Participants received placebo matched to VX-864 in the treatment period for 28 days.

Treatment:

Drug: Placebo

VX-864 100 mg

Experimental group

Description:

Participants received VX-864 100 milligrams (mg) every 12 hours (q12h) in the treatment period for 28 days.

Treatment:

Drug: VX-864

VX-864 300 mg

Experimental group

Description:

Participants received VX-864 300 mg q12h in the treatment period for 28 days.

Treatment:

Drug: VX-864

VX-864 500 mg

Experimental group

Description:

Participants received VX-864 500 mg q12h in the treatment period for 28 days.

Treatment:

Drug: VX-864